DiaMedica to Present at the MicroCap Conference on April 10th in New York City at the Essex House

DiaMedica to Present at the MicroCap Conference on April 10^th in New York City at the Essex House

MINNEAPOLIS, March 19, 2018 (GLOBE NEWSWIRE) – DiaMedica Therapeutics Inc. (“DiaMedica”) (TSX VENTURE:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, President and CEO, will  present at The MicroCap Conference at the Essex House, 160 Central Park South  New York on Tuesday April 10^th at 12:30pm ET.

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors.

For more information please visit www.microcapconf.com.

About DiaMedica Therapeutics:

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s lead product candidate DM199, a recombinant (synthetic) form of the KLK1 protein, is in clinical development for the treatment of acute ischemic stroke and chronic kidney diseases. 

DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”.  For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.

For further information, please contact:

Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Minneapolis, MN
Phone: (617) 899-5941
info@diamedica.com

Tweet this!

Released April 4, 2018